ARMR Sciences develops preventive countermeasures using organic molecules to activate the human immune system against bioweapons. The company is currently focused on creating a protective shield against Fentanyl exposure, with products in development for military, first responders, and individuals with opioid use disorder. Future pipeline candidates aim to provide defense against other potent synthetic threats like nitazenes and medetomidine.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for fentanyl overdose rely on emergency administration of naloxone, which requires timely intervention by bystanders or first responders, and often fails to prevent death. The rapid onset of fentanyl's effects and its increasing prevalence in illicit drugs necessitate a proactive approach to prevent overdoses before they occur.
Solution
ARMR Sciences is developing vaccines that prevent fentanyl from crossing the blood-brain barrier, thereby preventing respiratory depression and overdose. The vaccine stimulates the body's immune system to produce antibodies that bind to fentanyl, preventing it from reaching the brain and causing its deadly effects. This approach aims to provide a long-lasting protective barrier, reducing the reliance on emergency treatments and saving lives. The vaccines are designed to neutralize fentanyl upon exposure, preventing a high and facilitating its removal from the body.
Target Audience
The primary target audience includes individuals at high risk of fentanyl exposure, such as those with opioid use disorder, first responders, and military personnel, as well as public health organizations seeking preventative solutions to combat the opioid crisis.
Features
- Utilizes established vaccine technologies to stimulate an immune response against fentanyl.
- Designed to prevent fentanyl from entering the brain, thus preventing overdose.
- Aims to provide a proactive, long-lasting defense against fentanyl exposure.
- Targets multiple synthetic drug threats beyond fentanyl.
- Currently in pre-clinical and preparing for Phase 1 clinical trials (OVAX-100 and OVAX-200).